HHS Cannabis Rescheduling

FDA Commissioner Robert Califf's Thursday testimony sparked new conversations about the future of cannabis in the U.S. particularly concerning its medical and recreational classifications. In a recent note, senior analyst Pablo Zuanic from Zuanic & Associates highlights the...

Vice President Harris's urgent call to the DEA to expedite the rescheduling of cannabis marks a crucial turning point in national drug policy, as analyzed in a comprehensive equity research report by Zuanic & Associates. The report delves into the implications of Harris's push...

In a significant move to address long-standing issues within the U.S. cannabis policy, Vice President Kamala Harris called for the Drug Enforcement Administration (DEA) to expedite the rescheduling of marijuana under the Controlled Substances Act (CSA). "I'm sure DEA is working as...

Amidst President Joe Biden’s campaign promises, rescheduling marijuana from Schedule I to Schedule III is seen as the most impactful on the stock market, possibly positively fueling stock rallies. The possible reclassification of marijuana and its profound effects on the cannabis stock market...

In his latest cannabis sector equity report, senior analyst Pablo Zuanic of Zuanic & Associates offers a detailed examination of the cannabis sector's landscape in the fourth quarter of 2023. The report, “4Q23 Trends in Key States,” offers a crucial insight into the performances...

Amidst potential shifts in U.S. cannabis regulation, Lance Boldrey, leader of Cannabis Law Practice at Dykema Gossett PLLC, analyzes the potential impact of reclassifying cannabis to Schedule III under the Controlled Substance Act. Legal Challenges And Transition Strategies Boldrey said...

The anticipated shift of cannabis to Schedule III marks a pivotal moment for U.S. cannabis companies. In a detailed report, senior analyst Pablo Zuanic highlights key benefits of this change, including substantial improvements in cash flow and creditworthiness, influx of new capital, expansion...

The cannabis industry is poised for some serious growth owing to the historic clearance of the SAFER Banking Act by the Senate’s Banking Committee. Trulieve (OTCMKTS: TCNNF) CEO Kim Rivers couldn’t be clearer facing Benzinga’s Cannabis Capital Conference audience on Wednesday,...

Subversive Capital Advisor is set to launch its sixth exchange-traded fund (ETF) named Subversive Cannabis ETF (BATS: LGLZ) on the Cboe BZX Exchange, which is operated by Cboe Global Markets, a key global venue for listing exchange-traded products. Targeting long-term capital appreciation...

The U.S. Department of Health & Human Services (HHS) has recommended that marijuana be moved from Schedule I to Schedule III under federal law. This decision has widespread implications for the cannabis market's trajectory in 2024, touching on diverse areas ranging from policy and business...